NF-κB participates in several phases involved in drug resistance processes in particular, it modifies the expression of the mdr1 gene whose product, P-glycoprotein (P-gp), is a transporter of plasma membranes that induces the outflow of chemotherapy, not only in tumor induction and progression but also in resistance to therapy [16,31,32]. This evidence concerns the gene NFKB1 and neoplasm.